Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia

被引：77

作者：

Grob, Tim ^{[1
]}

Sanders, Mathijs A. ^{[1
]}

Vonk, Christian M. ^{[1
]}

Kavelaars, Francois G. ^{[1
]}

Rijken, Melissa ^{[1
]}

Hanekamp, Diana W. ^{[1
,2
]}

Gradowska, Patrycja L. ^{[1
]}

Cloos, Jacqueline ^{[2
]}

Floisand, Yngvar ^{[3
]}

van Marwijk Kooy, Marinus ^{[4
]}

Manz, Markus G. ^{[5
]}

Ossenkoppele, Gert J. ^{[2
]}

Tick, Lidwine W. ^{[6
]}

Havelange, Violaine ^{[7
]}

Lowenberg, Bob ^{[1
]}

Jongen-Lavrencic, Mojca ^{[1
]}

Valk, Peter J. M. ^{[1
]}

机构：

[1] Univ Med Ctr Rotterdam, Erasmus MC Canc Inst, Dept Hematol, Rotterdam, Netherlands

[2] Univ Amsterdam, Canc Ctr Amsterdam, Dept Hematol, Med Ctr, Amsterdam, Netherlands

[3] Oslo Univ Hosp, Dept Hematol, Oslo, Norway

[4] Isala Hosp, Dept Hematol, Zwolle, Netherlands

[5] Univ Hosp Zurich, Comprehens Canc Ctr Zurich, Dept Med Oncol & Hematol, Zurich, Switzerland

[6] Maxima Med Ctr, Dept Hematol, Eindhoven, Netherlands

[7] Clin Univ St Luc, Dept Hematol, Brussels, Belgium

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 04期

关键词：

MUTATIONS; FLT3; DIAGNOSIS; ADULTS; AML; EVOLUTION; YOUNGER; SAMPLES;

D O I：

10.1200/JCO.22.00715

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PURPOSEThe applicability of FLT3-internal tandem duplications (FLT3-ITD) for assessing measurable residual disease (MRD) in acute myeloid leukemia (AML) in complete remission (CR) has been hampered by patient-specific duplications and potential instability of FLT3-ITD during relapse. Here, we comprehensively investigated the impact of next-generation sequencing (NGS)-based FLT3-ITD MRD detection on treatment outcome in a cohort of patients with newly diagnosed AML in relation to established prognostic factors at diagnosis and other MRD measurements, ie, mutant NPM1 and multiparameter flow cytometry.METHODSIn 161 patients with de novo FLT3-ITD AML, NGS was performed at diagnosis and in CR after intensive remission induction treatment. FLT3-ITD MRD status was correlated with the cumulative incidence of relapse and overall survival (OS).RESULTSNGS-based FLT3-ITD MRD was present in 47 of 161 (29%) patients with AML. Presence of FLT3-ITD MRD was associated with increased risk of relapse (4-year cumulative incidence of relapse, 75% FLT3-ITD MRD v 33% no FLT3-ITD MRD; P < .001) and inferior OS (4-year OS, 31% FLT3-ITD MRD v 57% no FLT3-ITD MRD; P < .001). In multivariate analysis, detection of FLT3-ITD MRD in CR confers independent prognostic significance for relapse (hazard ratio, 3.55; P < .001) and OS (hazard ratio 2.51; P = .002). Strikingly, FLT3-ITD MRD exceeds the prognostic value of most generally accepted clinical and molecular prognostic factors, including the FLT3-ITD allelic ratio at diagnosis and MRD assessment by NGS-based mutant NPM1 detection or multiparameter flow cytometry.CONCLUSIONNGS-based detection of FLT3-ITD MRD in CR identifies patients with AML with profound risk of relapse and death that outcompetes the significance of most established prognostic factors at diagnosis and during therapy, and furnishes support for FLT3-ITD as a clinically relevant biomarker for dynamic disease risk assessment in AML.

引用

页码：756 / +

页数：11

共 26 条

[1] getITD for FLT3-ITD-based MRD monitoring in AML [J].

Blaette, Tamara J. ;

Schmalbrock, Laura K. ;

Skambraks, Sabrina ;

Lux, Susanne ;

Cocciardi, Sibylle ;

Dolnik, Anna ;

Doehner, Hartmut ;

Doehner, Konstanze ;

Bullinger, Lars .

LEUKEMIA, 2019, 33 (10) :2535-2539

[2] Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission [J].

Corces-Zimmerman, M. Ryan ;

Hong, Wan-Jen ;

Weissman, Irving L. ;

Medeiros, Bruno C. ;

Majeti, Ravindra .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2014, 111 (07) :2548-2553

[3] Targeting FLT3 mutations in AML: review of current knowledge and evidence [J].

Daver, Naval ;

Schlenk, Richard F. ;

Russell, Nigel H. ;

Levis, Mark J. .

LEUKEMIA, 2019, 33 (02) :299-312

[4] Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel [J].

Doehner, Hartmut ;

Estey, Elihu ;

Grimwade, David ;

Amadori, Sergio ;

Appelbaum, Frederick R. ;

Buechner, Thomas ;

Dombret, Herve ;

Ebert, Benjamin L. ;

Fenaux, Pierre ;

Larson, Richard A. ;

Levine, Ross L. ;

Lo-Coco, Francesco ;

Naoe, Tomoki ;

Niederwieser, Dietger ;

Ossenkoppele, Gert J. ;

Sanz, Miguel ;

Sierra, Jorge ;

Tallman, Martin S. ;

Tien, Hwei-Fang ;

Wei, Andrew H. ;

Lowenberg, Bob ;

Bloomfield, Clara D. .

BLOOD, 2017, 129 (04) :424-447

[5] A proportional hazards model for the subdistribution of a competing risk [J].

Fine, JP ;

Gray, RJ .

JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1999, 94 (446) :496-509

[6] Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse [J].

Garg, Manoj ;

Nagata, Yasunobu ;

Kanojia, Deepika ;

Mayakonda, Anand ;

Yoshida, Kenichi ;

Keloth, Sreya Haridas ;

Zang, Zhi Jiang ;

Okuno, Yusuke ;

Shiraishi, Yuichi ;

Chiba, Kenichi ;

Tanaka, Hiroko ;

Miyano, Satoru ;

Ding, Ling-Wen ;

Alpermann, Tamara ;

Sun, Qiao-Yang ;

Lin, De-Chen ;

Chien, Wenwen ;

Madan, Vikas ;

Liu, Li-Zhen ;

Tan, Kar-Tong ;

Sampath, Abhishek ;

Venkatesan, Subhashree ;

Inokuchi, Koiti ;

Wakita, Satoshi ;

Yamaguchi, Hiroki ;

Chng, Wee Joo ;

Kham, Shirley-Kow Yin ;

Yeoh, Allen Eng-Juh ;

Sanada, Masashi ;

Schiller, Joanna ;

Kreuzer, Karl-Anton ;

Kornblau, Steven M. ;

Kantarjian, Hagop M. ;

Haferlach, Torsten ;

Lill, Michael ;

Kuo, Ming-Chung ;

Shih, Lee-Yung ;

Blau, Igor-Wolfgang ;

Blau, Olga ;

Yang, Henry ;

Ogawa, Seishi ;

Koeffler, H. Phillip .

BLOOD, 2015, 126 (22) :2491-2501

[7] A CLASS OF K-SAMPLE TESTS FOR COMPARING THE CUMULATIVE INCIDENCE OF A COMPETING RISK [J].

GRAY, RJ .

ANNALS OF STATISTICS, 1988, 16 (03) :1141-1154

[8] 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party [J].

Heuser, Michael ;

Freeman, Sylvie D. ;

Ossenkoppele, Gert J. ;

Buccisano, Francesco ;

Hourigan, Christopher S. ;

Ngai, Lok Lam ;

Tettero, Jesse M. ;

Bachas, Costa ;

Baer, Constance ;

Bene, Marie-Christine ;

Bucklein, Veit ;

Czyz, Anna ;

Denys, Barbara ;

Dillon, Richard ;

Feuring-Buske, Michaela ;

Guzman, Monica L. ;

Haferlach, Torsten ;

Han, Lina ;

Herzig, Julia K. ;

Jorgensen, Jeffrey L. ;

Kern, Wolfgang ;

Konopleva, Marina Y. ;

Lacombe, Francis ;

Libura, Marta ;

Majchrzak, Agata ;

Maurillo, Luca ;

Ofran, Yishai ;

Philippe, Jan ;

Plesa, Adriana ;

Preudhomme, Claude ;

Ravandi, Farhad ;

Roumier, Christophe ;

Subklewe, Marion ;

Thol, Felicitas ;

van de Loosdrecht, Arjan A. ;

van der Reijden, Bert A. ;

Venditti, Adriano ;

Wierzbowska, Agnieszka ;

Valk, Peter J. M. ;

Wood, Brent L. ;

Walter, Roland B. ;

Thiede, Christian ;

Dohner, Konstanze ;

Roboz, Gail J. ;

Cloos, Jacqueline .

BLOOD, 2021, 138 (26) :2753-2767

[9] Clonal Evolution of Preleukemic Hematopoietic Stem Cells Precedes Human Acute Myeloid Leukemia [J].

Jan, Max ;

Snyder, Thomas M. ;

Corces-Zimmerman, M. Ryan ;

Vyas, Paresh ;

Weissman, Irving L. ;

Quake, Stephen R. ;

Majeti, Ravindra .

SCIENCE TRANSLATIONAL MEDICINE, 2012, 4 (149)

[10] Molecular Minimal Residual Disease in Acute Myeloid Leukemia [J].

Jongen-Lavrencic, M. ;

Grob, T. ;

Hanekamp, D. ;

Kavelaars, F. G. ;

al Hinai, A. ;

Zeilemaker, A. ;

Erpelinck-Verschueren, C. A. J. ;

Gradowska, P. L. ;

Meijer, R. ;

Cloos, J. ;

Biemond, B. J. ;

Graux, C. ;

Kooy, M. van Marwijk ;

Manz, M. G. ;

Pabst, T. ;

Passweg, J. R. ;

Havelange, V. ;

Ossenkoppele, G. J. ;

Sanders, M. A. ;

Schuurhuis, G. J. ;

Lowenberg, B. ;

Valk, P. J. M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (13) :1189-1199

← 1 2 3 →